Experimental drug trial sees every patient's cancer disappear

A new clinical trial involving dostarlimab has resulted in the absence of rectal cancer tumors in all patients that participated.

2 minutes & 14 seconds read time

A study on the cancer treatment titled "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer" has been accepted from publication in The New England Journal of Medicine.

The Memorial Sloan Kettering Cancer Center (MSK) is conducting a new trial administering the immunotherapy drug dostarlimab, sold under the brand name Jemperli, to patients with rectal cancer tumors. Only twelve patients have seen positive results as the trial is currently ongoing. However, every patient so far has entered remission following the treatment, and no tumors returned by their six-month check-ups.

All of the patients had tumors with genetic mutations known as mismatch repair deficiency (MMRd), making them less responsive to chemotherapy or radiation treatments and increasing the need for surgical removals. However, it also makes cancer cells more vulnerable to the immune system, especially when supported by immunotherapy drugs.

"When those mutations accumulate in the tumor, they stimulate the immune system, which attacks the mutation-ridden cancer cells. We thought, 'Let's try it before cancer metastasizes as a first line of treatment,'" said medical oncologist Luis Diaz Jr. at MSK.

"Very little is known about the duration of time needed to find out whether a clinical complete response to dostarlimab equates to cure. Whether the results of this small study conducted at Memorial Sloan Kettering Cancer Center will be generalizable to a broader population of patients with rectal cancer is also not known," explained Hanna K. Sanoff from the University of North Carolina at Chapel Hill in a commentary of the new findings.

"Despite these uncertainties, Cercek and colleagues and their patients who agreed to forgo standard treatment for a promising but unknown future with immunotherapy have provided what may be an early glimpse of a revolutionary treatment shift. If immunotherapy can be a curative treatment for rectal cancer, eligible patients may no longer have to accept functional compromise in order to be cured," Sanoff continued.

You can read more from the study here.

Adam's Top 3 Recommended Articles:

Read more: The Milky Way may have four 'malicious extraterrestrial civilizations'

Read more: This NASA spacecraft has caught stunning footage from around Jupiter

Read more: Val Kilmer's voice in 'Top Gun: Maverick' was entirely AI-generated

Experimental drug trial sees every patient's cancer disappear 01
Buy at Amazon

Rectal Cancer Awareness In This Family No One Fights Alone T-Shirt

TodayYesterday7 days ago30 days ago
* Prices last scanned on 6/24/2024 at 9:54 am CDT - prices may not be accurate, click links above for the latest price. We may earn an affiliate commission.

Adam grew up watching his dad play Turok 2 and Age of Empires on a PC in his computer room, and learned a love for video games through him. Adam was always working with computers, which helped build his natural affinity for working with them, leading to him building his own at 14, after taking apart and tinkering with other old computers and tech lying around. Adam has always been very interested in STEM subjects, and is always trying to learn more about the world and the way it works.

Newsletter Subscription

Related Tags